Heart failure

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 24, 2024
Bitcoin, Geisler, Research, News, Growth, Sale, AUV, Atrial fibrillation, Mergers and acquisitions, Acceleration, P.C, Boston Scientific, Amplitude, Marketing, J. P. Morgan, Stroke, Heart failure, Bankruptcy, DOJ, Subpoena duces tecum, Data mining, Vii, ECG, IRTC, Zio, FDA, SSS, Hut 8, COVID-19, Bloomberg Businessweek, Patient, Defendant, Justice, Cryptocurrency

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Intermountain Health Extends Leadership in Heart Care with Adoption of Advanced Robotic Technology

Retrieved on: 
Thursday, February 22, 2024
Intermountain West, Robotic magnetic navigation, Intermountain Health, RMN, MD, Intermountain Medical Center, Arrhythmia, Stroke, Risk, Heart failure, Safety, Genesis, Health, Patient, Science, Arrest, Robotics

Intermountain Medical Center is the leading provider of robotic heart rhythm care in Utah and the Intermountain Region.

Key Points: 
  • Intermountain Medical Center is the leading provider of robotic heart rhythm care in Utah and the Intermountain Region.
  • Electrophysiologists at the hospital have treated more than 1,000 patients using advanced robotic technology.
  • “Delivering outstanding patient care using the best technology and science is our primary focus at Intermountain,” said Michael Cutler, MD, cardiac electrophysiologist at Intermountain Medical Center.
  • “We look forward to continuing to support their successful and impactful robotic heart rhythm care program.”

Lee Health’s HealthPark Medical Center Named Among the Top 50 Hospitals for Heart Care in the U.S. for the 11th Time

Retrieved on: 
Tuesday, February 20, 2024
Hospital, CABG, AMI, Cardiology, IBM, IBM Watson, Heart failure, Angioplasty, Health care, Organization, Patient, Cardiac rehabilitation, Survival, HF, PCI, Nursing

Formerly known as the IBM Watson award, the PINC AI™ 50 Top Cardiovascular Hospitals™ represent the highest standard of cardiovascular care in the United States.

Key Points: 
  • Formerly known as the IBM Watson award, the PINC AI™ 50 Top Cardiovascular Hospitals™ represent the highest standard of cardiovascular care in the United States.
  • HealthPark Medical Center is one of only five hospitals in Florida and the only hospital in Southwest Florida to earn the designation.
  • The 2024 PINC AI™ 50 Top Cardiovascular Hospitals™ provide higher quality clinical care and are more efficient than their peers.
  • The PINC AI™ 50 Top Cardiovascular Hospitals™ program focuses on short-term, acute care, non-federal U.S. hospitals that treat a broad spectrum of cardiology patients.

Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference

Retrieved on: 
Tuesday, February 20, 2024
Artificial intelligence, CRF, Heart failure, Ultrafiltration, Therapy, Health, Machine learning, THT, Pharmaceutical industry

MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned activities at the upcoming Technology and Heart Failure Therapeutics conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, in Boston.

Key Points: 
  • MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced its planned activities at the upcoming Technology and Heart Failure Therapeutics conference (THT 2024), which is produced by the Cardiovascular Research Foundation (CRF), taking place March 4-6, in Boston.
  • Nuwellis will exhibit at booth #8, host a sponsored satellite symposium and highlight two late-breaking clinical abstracts during the conference.
  • Events where Nuwellis and its Aquadex SmartFlow® System will be featured at THT 2024 include:
    Title: Aquapheresis for Management of Decompensated Heart Failure: A Re-appraisal of AVOID-HF
    Title: AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial
    THT is a premier destination for pioneering data and comprehensive updates on heart failure treatments using medical technology.
  • The conference provides a forward-looking view of the heart failure therapeutics pipeline, delving into the role of emerging technologies like artificial intelligence and machine learning in heart failure patient care.

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

Retrieved on: 
Tuesday, February 20, 2024
Orion Corporation, Pulmonary hypertension, Heart failure, Therapy, IP, Modified, Pharmaceutical industry

Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire world

Key Points: 
  • Amendment to existing exclusive license agreement with Orion Corporation expands Tenax’s territory rights from North America, to the entire world
    Improved net sales royalty rate structure, now ranging from high single-digit to low-teen percentages.
  • “We are delighted to enter into this important amendment to our license from Orion.
  • We have achieved a key corporate objective by expanding our development, IP, and commercial territory rights for levosimendan beyond North America,” said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics.
  • “Our efforts to secure global commercial rights and leverage the additional potential IP protection around the world enable us to build significant shareholder value as we advance levosimendan into Phase 3 testing,” said Mr. Giordano.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm, Hut 8, Xponential, and Amplitude and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, February 20, 2024
Bitcoin, Geisler, Research, News, Growth, Sale, AUV, Atrial fibrillation, Mergers and acquisitions, Acceleration, P.C, Boston Scientific, Amplitude, Marketing, J. P. Morgan, Stroke, Heart failure, Bankruptcy, DOJ, Subpoena duces tecum, Data mining, Vii, ECG, IRTC, Zio, FDA, SSS, Hut 8, COVID-19, Bloomberg Businessweek, Patient, Defendant, Justice, Cryptocurrency

The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.

Key Points: 
  • The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
  • The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
  • These types of heart monitors that are approved for high-risk patients and provide near real-time alerts are also referred to as “real-time” monitors.
  • As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

Access TeleCare and UT Southwestern Project Aims to Improve Outcomes for Rural Patients with Heart Failure

Retrieved on: 
Wednesday, March 6, 2024
Research, Hospitals, Health Technology, Telemedicine, Virtual Medicine, Cardiology, Managed Care, General Health, Health, Science, Other Science, Chest pain, Bangladesh Technical Education Board, American Heart Association, Telehealth, AHA, Stroke, MHealth, Heart failure, American Heart, Telecare, Arrhythmia, Internal medicine, Associate, Cardiac rehabilitation, Patient, Hospital

Access TeleCare and the UT Southwestern Medical Center, with integral support from the American Heart Association (AHA), are leading a two-year project to evaluate options to improve the care of patients with heart failure in rural communities across the country.

Key Points: 
  • Access TeleCare and the UT Southwestern Medical Center, with integral support from the American Heart Association (AHA), are leading a two-year project to evaluate options to improve the care of patients with heart failure in rural communities across the country.
  • Create a registry of 1,000 rural patients with heart failure who are hospitalized in rural hospitals that have a teleCardiology program to document patterns of care.
  • “Access TeleCare has long been a pioneer in eliminating barriers to timely specialty care in rural communities by bringing specialists to patients through the power of telemedicine,” said Chris Gallagher, M.D., CEO, Access TeleCare.
  • These programs give hospitals 24/7 access to cardiologists for patients hospitalized with heart failure, arrhythmias, chest pain, and other heart-related conditions.

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
Wednesday, March 6, 2024
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Peripheral edema, Thoracic duct, Acute decompensated heart failure, Ohio State University, Physiology, Drainage, Congestion, Heart failure, ADHF, Cell biology, Death, Patient, Lymphatic system, Medicine, THT, Tissue, Pharmaceutical industry

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

FIRE1 Completes Enrollment in U.S. Early Feasibility Study of Innovative Remote Heart Failure Monitoring System

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Surgery, Health Technology, Clinical Trials, Cardiology, Division, Hypervolemia, Surgeon, Rochester General Hospital, Ohio State University, Weill Cornell Medicine, Hospital, Duke University Hospital, Inferior vena cava, Heart failure, Patient, Medicine, IVC, Ageing, Physician, Pressure, Medical imaging

Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.

Key Points: 
  • Early Feasibility Study (FUTURE-HF2) of its FIRE1™ System for remote heart failure monitoring.
  • The FIRE1 System is the first device designed to directly measure a patient’s volume status by measuring the largest vein in the body where most fluid is stored – the inferior vena cava (IVC) – to better manage heart failure.
  • FIRE1 seeks to transform heart failure management by enabling patients to monitor and control their fluid volume themselves with a consumer-friendly device at home, similar to how continuous glucose monitoring transformed diabetes care.
  • “It is gratifying to see the physician interest in our novel technology that earlier studies suggest should be a more sensitive measure than pressure in monitoring heart failure,” said FIRE1 CEO and President Conor Hanley.

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

Retrieved on: 
Tuesday, February 27, 2024
Health, Clinical Trials, Research, Cardiology, Science, Biotechnology, Workload, FDA, Food, Surgeon, Pulmonary hypertension, Heart failure, Safety, Heart, Patient, DRS, Pulmonary artery, Pharmaceutical industry

Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.

Key Points: 
  • Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana.
  • The Aria CV Pulmonary Hypertension System is an implantable gas-filled balloon that is introduced percutaneously and functions in the main pulmonary artery to alleviate the excessive workload on the right heart that results in right heart failure.
  • Aria’s device is designed to restore the benefits of a healthy pulmonary artery by reducing cardiac workload and enhancing blood flow through the lungs.
  • “The successful patient implant of the Gen 2 system is a significant milestone in realizing our mission to improve the lives of those suffering from pulmonary hypertension, a life-threatening disease that can lead to heart failure,” said Dan Gladney, President and CEO of Aria CV.